$SAVA
Cassava Sciences to Hold Corporate Update on November 25th
Event Details:
Date:
Monday, November 25th
Time:
8:00 a.m. Eastern Time
Webcast:
lifescievents.com/event/cassava/
Filana Therapeutics
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc., formerly Pain Therapeutics Inc.) is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam (formerly known as PTI-125 and sumifilam) as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. More on Wikipedia
-
Cassava Sciences
@CassavaSciences
-
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer.
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
-Rethink Dosing Completed
#endalz #simufilam
www.cassavasciences.com/static-files/d46ee533-09d3-42d8-b… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Resolves SEC Investigation
www.cassavasciences.com/node/17196/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Re-recording of disrupted 09/09/24 interview between CEO Rick Barry and HCW analyst.
journey.ct.events/view/d574c934-b104-45ac-bf42-07f169ce0d11 -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Names Rick Barry as Chief Executive Officer
www.cassavasciences.com/node/17156/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference.
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
www.cassavasciences.com/news-releases/news-release-detail…
•$207.3 Million in Cash and Cash Equivalents at June 30, 2024.
•Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution.
•Conference Webcast Scheduled for Today at 8:30AM ET. -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
www.cassavasciences.com/node/17111/pdf -
Cassava Sciences
@CassavaSciences
$SAVA Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Expansion of Open-Label Extension Trials
www.cassavasciences.com/node/17096/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
www.cassavasciences.com -
Cassava Sciences
@CassavaSciences
$SAVA
www.cassavasciences.com/news-releases/news-release-detail…
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
www.cassavasciences.com/node/16806/pdf
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
-$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.
-A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies.
-Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.
-Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Company. -
Cassava Sciences
@CassavaSciences
-
Cassava Sciences
@CassavaSciences
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
$SAVA
-Shareholders of Record Received Warrants to Purchase Shares of Common Stock.
-Warrants Trade on Nasdaq Under the Ticker “SAVAW”.
-Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional 0.5 of a Common Share Per Warrant.
www.cassavasciences.com/node/16751/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Appoints Three New Members to its Board of Directors
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
-Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.
-Over 1,900 patients randomized in on-going Phase 3 trials.
-Top-line results for 52-week Phase 3 trial expected approximately year-end 2024.
-Top-line results for 76-week Phase 3 trial expected approximately mid-year 2025.
-MRI safety data suggests simufilam is not associated with ARIA.
-$142.4 Million in cash and cash equivalents at September 30, 2023
www.cassavasciences.com/node/16631/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
$SAVA
#endalz
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.
Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.
www.cassavasciences.com/node/16626/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
CUNY’s report makes no findings of data manipulation.
The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.
CUNY’s report finds that internal record-keeping failures “ prevented us [CUNY] from making an objective assessment” of research misconduct.
Leak of CUNY report preceded by massive increase in short selling.
www.cassavasciences.com/node/16596/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY.
CEO to Present on Wednesday, October 11th, at 10:30am ET
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical Trial.
A Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately 1,100 Patients.
#endalz
www.cassavasciences.com/node/16561/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
www.cassavasciences.com/node/16556/pdf
Cassava Sciences
@CassavaSciences
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.
The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
www.cassavasciences.com/node/16526/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
www.cassavasciences.com/node/16496/pdf -
Cassava Sciences
@CassavaSciences
$SAVA Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
www.cassavasciences.com/node/16466/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease.
#endalz
www.cassavasciences.com/node/16451/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
New Research Shows Simufilam Suppresses Overactive mTOR.
www.cassavasciences.com/node/16446/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
New Publication Highlights Basic Science Supporting Simufilam.
www.cassavasciences.com/node/16436/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences to Present at the Jefferies Global Healthcare Conference.
Thursday, June 8th at 4:30 pm Eastern time.
www.cassavasciences.com/node/16426/pdf
Cassava Sciences
@CassavaSciences
Live Webcast:
wsw.com/webcast/jeff281/sava/1846130
Cassava Sciences
@CassavaSciences
Archived Replay:
www.cassavasciences.com/company-presentations -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
www.cassavasciences.com/node/16406/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A.
Data to be presented at the European Society of Endocrinology, May 13-16th.
www.cassavasciences.com/node/16366/pdf -
Cassava Sciences reposted
Kevin Lowe
@SmokeMonkey89
What’s worse is short selling a biomedical company that has the potential to be the first ever drug to not only slow Alzheimer’s but potentially improve cognition. Cassava Sciences ($SAVA) is currently in Phase 3 and has been relentlessly shorted by these horrible people.
-
Cassava Sciences
@CassavaSciences
$SAVA #endalz
Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.
Completion of patient enrollment for Phase 3 program still expected Q4 2023.
$187.5 Million Cash and Cash Equivalents at March 31, 2023.
www.cassavasciences.com/static-files/f715431b-9d0a-4583-a… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
Statement of changes in beneficial ownership of securities
www.cassavasciences.com/node/16271/html -
Cassava Sciences
@CassavaSciences
$SAVA Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
-953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies
www.cassavasciences.com/node/16231/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
www.cassavasciences.com/node/16211/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
💐
$SAVA
www.cassavasciences.com/node/16186/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
$SAVA
#endalz
www.cassavasciences.com/node/16171/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering.
www.cassavasciences.com/node/16151/pdf
Cassava Sciences
@CassavaSciences
www.cassavasciences.com/static-files/0e3a51e0-40b5-4cd9-b…
$SAVA -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock.
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
www.cassavasciences.com/node/16096/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
www.cassavasciences.com/node/16086/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Expansion of Leadership Team
www.cassavasciences.com/node/16066/pdf
$SAVA
Chris Cook, A Skilled Litigator, To Join Management Team as General Counsel. -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Initiation of an Open-label Extension Study
$SAVA
#endalz
www.cassavasciences.com/node/16061/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
FRIEDMANN NADAV
www.cassavasciences.com/static-files/5bdc6f4c-c794-434e-b… -
Cassava Sciences
@CassavaSciences
www.cassavasciences.com/static-files/0d852d7e-0076-41ca-b…
$SAVA -
Cassava Sciences
@CassavaSciences
$SAVA
ROBERTSON SANFORD
www.cassavasciences.com/static-files/aac58d24-f661-4ec2-8… -
Cassava Sciences
@CassavaSciences
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
www.cassavasciences.com/node/16036/pdf
$SAVA -
Cassava Sciences
@CassavaSciences
$SAVA FORM 4
www.cassavasciences.com/node/16021/html
BARRY RICHARD -
Cassava Sciences
@CassavaSciences
$SAVA
KUPIEC JAMES WILLIAM
www.cassavasciences.com/static-files/bce50f02-8f01-4ae6-b… -
Cassava Sciences
@CassavaSciences
$SAVA
No Evidence of Data Manipulation in Science Publication on Simufilam
www.cassavasciences.com/node/16006/pdf -
Cassava Sciences
@CassavaSciences
www.sec.gov/Archives/edgar/data/1069530/00010695302200003…
$SAVA -
Cassava Sciences
@CassavaSciences
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
www.cassavasciences.com/node/15976/pdf
$SAVA
#endalzPost not available here, view on X
Cassava Sciences
@CassavaSciences
63% of the 100 Patients Showed an Improvement in ADAS-Cog11 Scores, and This Group of Patients Improved an Average of 5.6 Points (S.D. ± 3.8).
Cassava Sciences
@CassavaSciences
Cognition Maintenance Study - Completion of Patient Enrollment is Expected Q4 2022.
-
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Responds to Media Reports
www.cassavasciences.com/node/15961/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Letter To Science Editor of the New York Times:
www.cassavasciences.com/static-files/c45c3dde-0a21-4f68-9…
@nytimes
@apoorva_nyc -
Cassava Sciences
@CassavaSciences
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
$SAVA
www.cassavasciences.com/node/15896/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Webcast Details for Cassava Sciences’ Upcoming Fireside Chat
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates.
– Stakeholders Are Invited to Submit Questions via Email.
www.cassavasciences.com/node/15866/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
New Form 10-K for Cassava Sciences, Inc.
www.cassavasciences.com/static-files/3a15615c-0f6c-4526-b… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
www.cassavasciences.com/node/15821/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients
“The news is very welcome but not surprising,” said Remi Barbier, President & CEO. “We said from the outset that the allegations are false.
www.cassavasciences.com/node/15796/pdf
Cassava Sciences
@CassavaSciences
I think the message may be that the FDA’s citizen petition privilege is not to be trifled with by stock market participants.”
-
Cassava Sciences
@CassavaSciences
$SAVA Form SC 13G/A / Form 5
www.cassavasciences.com/static-files/61dd17ab-ceb9-40d0-9… -
Cassava Sciences
@CassavaSciences
$SAVA
An amendment to the SC 13G filing
www.cassavasciences.com/static-files/71000b05-433b-4184-9… -
Cassava Sciences
@CassavaSciences
$SAVA
New Form 8-K for Cassava Sciences, Inc.
#endalz
www.cassavasciences.com/static-files/1637fec1-4b4b-4a56-a… -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Corporate presentation - January 2022
www.cassavasciences.com/company-presentations -
Cassava Sciences
@CassavaSciences
$SAVA
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease.
#endalz
www.cassavasciences.com/node/15751/pdf
Cassava Sciences
@CassavaSciences
Please visit : rethink-alz.com
$SAVA -
Cassava Sciences
@CassavaSciences
$SAVA Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication
#endalz
www.cassavasciences.com/node/15736/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
Website to recruit subjects into Cassava Sciences clinical trials is up!
rethink-alz.com/index.html
Source: @lindsaybbar
#endalz
#share -
Cassava Sciences
@CassavaSciences
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
$SAVA
#endalz
www.cassavasciences.com/node/15721/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Reports Third Quarter 2021 Financial Results
$SAVA
#endalz
www.cassavasciences.com/node/15706/pdf -
Cassava Sciences
@CassavaSciences
$SAVA
CTAD conference will be in Boston on November 9-12, 2021
Poster presented onsite:
interim Results of an Open-label Study of Simufilam in Mild-to-Moderate Alzheimer’s Disease
#ctad21 @CTADconference #alzheimers #clinicaltrials #endalz
www.ctad-alzheimer.com/files/files/Program_CTAD2021_1oct … -
Cassava Sciences
@CassavaSciences
$SAVA
Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences’ Lead Drug Candidate
#endalz
www.cassavasciences.com/node/15681/pdf -
Cassava Sciences
@CassavaSciences
A Proclamation on National Alzheimer’s Disease Awareness Month, 2021
💜 www.whitehouse.gov/briefing-room/presidential-actions/202… 💜
#endalz
#alzheimersawarenessmonth
#simufilam
@WhiteHouse
@POTUS
@VP
$SAVA -
Cassava Sciences
@CassavaSciences
During November, National Alzheimer's Disease Awareness month aims at making the general public more aware of the disease and the scale of it among the U.S. population, as well as bring new light potential care options for those affected. 💜
#alzheimers
$SAVA
#endalz -
Cassava Sciences
@CassavaSciences
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
$SAVA
#endalz
www.cassavasciences.com/node/15676/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease
$SAVA
#endalz
www.cassavasciences.com/node/15586/pdf -
Cassava Sciences
@CassavaSciences
« We remember their Love when they can no longer remember »
World alzheimer’s day
21/09/21
@alzassociation
#endalz
#knowdimentia
#knowalzheimer
#defeatalz
$SAVA -
Cassava Sciences
@CassavaSciences
On-Going or Planned for 2021 :
#endalz
#deafeatalz
#alzheimersdisease
$SAVA
Source : www.cassavasciences.com/static-files/9e8933b4-b67f-4e9c-b… -
Cassava Sciences
@CassavaSciences
Cassava corporate presentation - September 2021
#endalz
#alzheimer
$SAVA
www.cassavasciences.com/static-files/9e8933b4-b67f-4e9c-b… -
Cassava Sciences
@CassavaSciences
Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference
$SAVA
#endalz
www.cassavasciences.com/node/15576/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences hit by false allegations. Hit job by a law firm that admits it represents short sellers, makes its case in the Court of Public Opinion (as opposed to a Court of Law). Unreal. Here is Cassava Sciences’ most recent response. #endalz
Source linkdn : @lindsaybbar
Cassava Sciences
@CassavaSciences
-
Cassava Sciences
@CassavaSciences
Cassava Sciences Releases a Public Statement Regarding Recent Allegations
$SAVA
#endalz
www.cassavasciences.com/node/15561/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients
$SAVA
#endalz
www.cassavasciences.com/node/15546/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Responds to Allegations
$SAVA
#endalz
www.cassavasciences.com/node/15536/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
$SAVA
#endalz
www.cassavasciences.com/node/15526/pdf -
Cassava Sciences
@CassavaSciences
Clinical studies to test a new and promising scientific approach for the treatment and diagnosis of Alzheimer's disease.
Simufilam was developed in-house. Substantially funded by peer-review research grant awards from the National Institutes of Health (NIH)
$SAVA
#endalz @NIH -
Cassava Sciences
@CassavaSciences
“I missed this earlier, but simufilam is featured as a promising drug in the Alzheimer's pipeline in this Medscape Psychiatry article”. #endalz #biomarkers #alzheimers
Via: Lindsay Burns Linkdn
$SAVA
www.medscape.com/viewarticle/956044 -
Cassava Sciences reposted
Austin Business Journal
@MyABJ
Wall Street is abuzz about Austin-based @CassavaSciences as it prepares to deliver a key update on its new Alzheimer's drug, simufilam. Can the drug become a breakthrough treatment for Alzheimer's? @alzassociation @alzheimerssoc @alzfdn
www.bizjournals.com/austin/news/2021/07/28/cassava-scienc… -
Cassava Sciences
@CassavaSciences
#2021 What a year so far it has been !
End-of-phase 2 meeting with FDA to gain general agreement around a Phase 3 clinical development program in Alzheimer’s disease – completed Jan 2021
✓ Results of interim analysis (6-month) of open-label study - completed Feb 2021Post not available here, view on X
Cassava Sciences
@CassavaSciences
✓ Meet target enrollment (150 subjects) for open-label study of simufilam – completed June 2021& on-going
✓ Data presentation at AAIC (6-month biomarker; 9-months safety & cognition; SavaDx).
#endalz $SAVA
Cassava Sciences
@CassavaSciences
And many more to come !
Thank you for following our fight and mission to defeat and #endalz -
Cassava Sciences
@CassavaSciences
Another good write-up of simufilam for Alzheimer’s disease. Phase 3 trials starting this fall! Follow us and stay up to date #biomarkers #endalz
$SAVA
@Being_Patient_
www.beingpatient.com/simufilam-dementia-alzheimers/ -
Cassava Sciences
@CassavaSciences
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions.Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease.
$SAVA
Cassava Sciences
@CassavaSciences
Cassava Sciences
@CassavaSciences
. For more information, please visit: www.cassavasciences.com.
-
Cassava Sciences
@CassavaSciences
Results are in , 71% so many loved ones are touched …. Thank you for participating.
$SAVA
#endalz
@alzassociation
Cassava Sciences
@CassavaSciences
Did you know poll : “ Scientists estimate that by 2050 someone in the United States will develop the disease every 33 seconds. “
Have you ever had a familly member or relative that have been touched by #alzheimers ?
#endalz #defeatalz
$SAVA
@alzassociation -
Cassava Sciences
@CassavaSciences
Simufilam ,is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease.
Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain
$SAVA #endalz
www.cassavasciences.com/simufilam -
Cassava Sciences
@CassavaSciences
Did you know poll : “ Scientists estimate that by 2050 someone in the United States will develop the disease every 33 seconds. “
Have you ever had a familly member or relative that have been touched by #alzheimers ?
#endalz #defeatalz
$SAVA
@alzassociation -
Cassava Sciences
@CassavaSciences
“Alzheimer’s is literally killing us, and the only way to fight this ‘crime’ is through a groundswell of people who continue to raise their voices and funds to ensure it gets the attention it deserves.” – Tess Gerritsen
$SAVA
#endalz
Cassava Sciences
@CassavaSciences
“People with Alzheimer’s deserve to be seen, so that we can find a cure.” – Julianne Moore
#joinus
#endalz
www.cassavasciences.com/static-files/c45b6f43-ccc1-4391-b…
Cassava Sciences
@CassavaSciences
-
Cassava Sciences
@CassavaSciences
Please Meet : Dr. Lindsay Burns PHD
Lindsay H. Burns, PhD has been the lead scientist and Olympic champion . She has been on Cassava Sciences’ Alzheimer’s disease program since she and Dr. Hoau-Yan Wang discovered simufilam's novel target.
1/3
Cassava Sciences
@CassavaSciences
Dr. Burns has led the program through medicinal chemistry, lead profiling and IND-enabling studies to its current stage of clinical trials in Alzheimer’s disease patients. Trained in neuropsychology at the University of Cambridge and Harvard College,
2/3
Cassava Sciences
@CassavaSciences
Dr. Burns has a broad background in neuroscience and neurodegenerative disease that spans functional in vitro assays, preclinical models of disease and cognitive/behavioral testing.
$SAVA #endalz @WomenAgstAlz @WomenScienceDay @4womeninscience @WomensHealthMag @nytimes
3/3 -
Cassava Sciences
@CassavaSciences
If you missed it ?
Cassava Sciences Conference Call for Second Quarter Financial Results
Replay Dial-In Numbers
Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Pin Number: 3249415
$SAVA
#endalz
#indatawetrust
Cassava Sciences
@CassavaSciences
Replay Start: Tuesday August 3, 2021, 12:00 PM ET
Replay Expiry: Tuesday August 17, 2021, 11:59 PM ET -
Cassava Sciences
@CassavaSciences
Cassava Sciences Reports Second Quarter 2021 Financial Results
www.cassavasciences.com/node/15501/pdf
$SAVA
#endalz
#joinus -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Conference Call for Second Quarter Financial Results
www.cassavasciences.com/node/15496/pdf
$SAVA
#endalz
#joinus -
Cassava Sciences
@CassavaSciences
For those of you not able to hear my talk at AAIC, here is a great write-up of the simufilam data on Seeking Alpha. With all the caveats of an open-label study,
$SAVA
#endalz
seekingalpha.com/amp/article/4443027-casava-sciences-simu…
Cassava Sciences
@CassavaSciences
3-point cognitive improvement from baseline at 9 months on ADAS-Cog11 coupled with improvements from baseline in 8 CSF biomarkers at 6 months ranging from 18-84% are unparalleled. #endalz
@alzassociation
@JoeSpringer
Source : Lindsay Burns via Linkdn -
Cassava Sciences
@CassavaSciences
We would like to take a moment to thank everyone who attended #aaic21 and the @alzassociation and especially the patients and families touched by this awful disease, as we stand behind our effort to keep moving forward on defeating #alzheimer #endalz
$SAVA
Please stay tuned! -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease
$SAVA #endalz #aaic2021
www.cassavasciences.com/node/15481/pdf -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease
www.cassavasciences.com/node/15486/pdf
$SAVA #endalz #aaic2021 -
Cassava Sciences
@CassavaSciences
Get ready @alzassociation as Lindsay H. Burns PhD - Sr. VP, Neuroscience
Share encouraging data at 10:28 am ET
At #aaic2021 #endalz #sava $SAVA -
Cassava Sciences
@CassavaSciences
On Thursday, July 29th, at approximately 11 am ET, simufilam will be featured in a live podium presentation at AAIC
Watch and Listen Live to :
Lindsay H. Burns PhD - Sr. VP, Neuroscience
Share encouraging 9month Simufilam data
$SAVA #aaic2021 -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam
$SAVA #aaic2021 #endalz
www.cassavasciences.com/node/15456/pdf -
Cassava Sciences
@CassavaSciences
Looking forward for you to Tune in next week for our Podium Presentation.
The Alzheimer’s Association International Conference (AAIC) is the largest and most influential international meeting dedicated to advancing dementia science.
@alzassociation $SAVA #endalz I -
Cassava Sciences
@CassavaSciences
Looking forward seeing you at #aaic21 !
$SAVA @alzassociation
-On Monday, July 26th, New Clinical Data for SavaDx to be Shared in
a Poster presentation
- On Thursday, July 29th, Encouraging new Clinical Data for Simufilam to be Featured in a Podium Presentation -
Cassava Sciences
@CassavaSciences
Tune in @alzassociation
- On Monday, July 26th, New Clinical Data for SavaDx to be Shared in
a Poster Presentation
- On Thursday, July 29th, New Clinical Data for Simufilam to be Featured in a Podium Presentation
$SAVA
#aaic #endalz -
Cassava Sciences
@CassavaSciences
“Cassava Sciences’ contributions to AAIC showcase our efforts to develop innovative product candidates for people living with Alzheimer’s disease,” said Remi Barbier, President and CEO.
@alzassociation $SAVA #endalz
Cassava Sciences
@CassavaSciences
“We are honored AAIC’s scientific committee has invited us to present the latest clinical dataset for simufilam in an oral presentation on Thursday, July 29th.”
@alzassociation $SAVA #endalz -
Cassava Sciences
@CassavaSciences
Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference
$SAVA #endalz
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
“Premier Research is pleased to be Cassava Sciences’ CRO of choice for this pivotal program,” said Krista Armstrong, Senior Vice President, Clinical Development Services and Global Head of Neuroscience, Premier Research.
Cassava Sciences
@CassavaSciences
“Premier Research has deep experience in conducting complex studies in neuroscience. We look forward to bringing our extensive knowledge and experience in Alzheimer’s disease to Cassava Sciences’ pivotal Phase 3 program of simufilam.” $SAVA
-
Cassava Sciences
@CassavaSciences
The open-label study has completed its target enrollment of 150 subjects. By physician and patient request, clinical sites may continue to enroll additional subjects up through the initiation of the Company’s Phase 3 pivotal program of simufilam.
$SAVA -
Cassava Sciences
@CassavaSciences
Upcoming Data Release $SAVA
#endalz -
Cassava Sciences
@CassavaSciences
SavaDx was evaluated for its ability to detect treatment effects of simufilam versus placebo in a randomized, controlled study that enrolled 64 patients with Alzheimer’s disease. The SavaDx clinical dataset will be presented at AAIC the week of July 26-30th $SAVA #endalz
-
Cassava Sciences
@CassavaSciences
« Updated « Milestones « $SAVA
-
Cassava Sciences
@CassavaSciences
Below is a list of participating research sites for the ongoing open-label extension study of simufilam, an investigational drug candidate in Alzheimer’s disease. Please check back for additional studies and expanded U.S. and Canadian sites.
-
Cassava Sciences
@CassavaSciences
• Key drivers of our clinical development program:
» A decade of research in basic biology
» Clear scientific rationale
» Published pre-clinical results
» Well-understood mechanism of action
» Clean safety profile
Cassava Sciences
@CassavaSciences
» Evidence of target engagement in patients
» Unprecedented CSF biomarker data
» Phase 2b clinical results
» Early data on cognition and behavior
» Successful End-of-Phase 2 meeting with FDA
Cassava Sciences
@CassavaSciences
Simufilam is Phase 3 ready in 2021.
Our scientific approach is unique, our clinical data is highly differentiated. -
Cassava Sciences
@CassavaSciences
The National Institutes of Health (NIH) continues to provide our research programs with substantial scientific and financial support. Academics and scientific and medical advisors supply us with substantial technical support
#endalz $SAVA -
Cassava Sciences
@CassavaSciences
SavaDx is our blood-based diagnostic to detect Alzheimer’s disease.
The goal of SavaDx is to make the detection of Alzheimer’s disease as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.
$SAVA #detectalz #endalz #defeatalz -
Cassava Sciences
@CassavaSciences
Cassava Sciences still on track to present the data , fundamentals and mission has not changed
#endalz #defeatalzheimer
$SAVA
Hear 👂 us at AAIC 📢 July 26-29th 2021 -
Cassava Sciences
@CassavaSciences
Cassava Sciences not only working on defeating Alzheimer, but also working on detecting it early with SavaDx
$SAVA
#endalz
#endalzheimers
www.cassavasciences.com/static-files/7aa9f438-9c73-4380-a… -
Cassava Sciences
@CassavaSciences
Stay tuned for the AAIC conference on july 29th in Denver CO , Cassava Sciences will be presenting it’s Data
$SAVA -
Cassava Sciences
@CassavaSciences
« Meet the TEAM »
$SAVA -
Cassava Sciences
@CassavaSciences
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease $SAVA
www.cassavasciences.com/node/15411/pdf -
Cassava Sciences
@CassavaSciences
www.cassavasciences.com/news-releases/news-release-detail…
$SAVA -
Cassava Sciences
@CassavaSciences
Cassava Sciences plans to announce results of a pre-specified interim analysis that summarizes safety and cognition. The Company will present these data July 26 - 29th at the 2021 Alzheimer’s Association International Conference (AAIC). $SAVA
Cassava Sciences
@CassavaSciences
AAIC’s scientific committee has invited the Company’s scientists to present the dataset as an oral presentation.
-
Cassava Sciences
@CassavaSciences
Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference
$SAVA
www.cassavasciences.com/news-releases/news-release-detail… -
Cassava Sciences
@CassavaSciences
Expected 2021 milestones
$SAVA -
Cassava Sciences
@CassavaSciences
Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors
www.cassavasciences.com/node/15381/pdf -
Cassava Sciences
@CassavaSciences
Phase 2b Summary of Results - CSF Biomarkers
$SAVA
www.cassavasciences.com/static-files/e2630158-8c5d-40f5-8… -
Cassava Sciences
@CassavaSciences
Cassava Sciences Fireside Chat at Riley’S
$SAVA
www.webcaster4.com/Webcast/Page/2433/41052 -
Cassava Sciences
@CassavaSciences
Cassava Sciences Corporate Presentation
$SAVA
www.cassavasciences.com/static-files/e2630158-8c5d-40f5-8…
































